Verdinexor, a novel selective inhibitor of nuclear export, reduces influenza a virus replication in vitro and in vivo

Journal of Virology

Volumn 88, Issue 17, 2014, Pages 10228-10243

  Perwitasari, Olivia ^a   Johnson, Scott ^a   Yan, Xiuzhen ^a   Howerth, Elizabeth ^a   Shacham, Sharon ^b   Landesman, Yosef ^b   Baloglu, Erkan ^b   McCauley, Dilara ^b   Tamir, Sharon ^b   Mark Tompkins, S ^a   Tripp, Ralph A ^a  

^a UNIVERSITY OF GEORGIA   (United States)

^b Karyopharm Therapeutics   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ANTIVIRUS AGENT; CELL RECEPTOR; ENZYME INHIBITOR; EXPORTIN 1 PROTEIN; KARYOPHERIN;

ACTIVE TRANSPORT; ANIMAL; ANTAGONISTS AND INHIBITORS; BAGG ALBINO MOUSE; CELL LINE; CHEMOPROPHYLAXIS; DISEASE MODEL; DRUG EFFECTS; FEMALE; HUMAN; INFLUENZA VIRUS A; INFLUENZA VIRUS B; METABOLISM; ORTHOMYXOVIRIDAE INFECTIONS; PHYSIOLOGY; PROCEDURES; VIRUS REPLICATION;

ACTIVE TRANSPORT, CELL NUCLEUS; ANIMALS; ANTIVIRAL AGENTS; CELL LINE; CHEMOPREVENTION; DISEASE MODELS, ANIMAL; ENZYME INHIBITORS; FEMALE; HUMANS; INFLUENZA A VIRUS; INFLUENZA B VIRUS; KARYOPHERINS; MICE, INBRED BALB C; ORTHOMYXOVIRIDAE INFECTIONS; RECEPTORS, CYTOPLASMIC AND NUCLEAR; VIRUS REPLICATION;

EID: 84914702498     PISSN: 0022538X     EISSN: 10985514     Source Type: Journal    
DOI: 10.1128/JVI.01774-14     Document Type: Article

References (87)

1. Fiore AE, Uyeki TM, Broder K, Finelli L, Euler GL, Singleton JA, Iskander JK, Wortley PM, Shay DK, Bresee JS, Cox NJ, Centers for Disease Control and Prevention (CDC). 2010. Prevention and control of influenza with vaccines: recommendations of the Advisory Committee on Immunization Practices (ACIP), 2010.MMWRRecomm. Rep. 59(RR-8): 1-62. http://www.cdc.gov/mmwr/preview/mmwrhtml/rr5908a1.htm.
2. Hoyert DL, Kung H-C, Smith BL. 2005. Deaths: preliminary data for 2003. Natl. Vital Stat. Rep. 53:1-48. http://www.cdc.gov/nchs/data/nvsr/nvsr53/nvsr53_15.pdf.
3. Podewils LJ, Liedtke LA, McDonald LC, Hageman JC, Strausbaugh LJ, Fischer TK, Jernigan DB, Uyeki TM, Kuehnert MJ. 2005. A national survey of severe influenza-associated complications among children and adults, 2003-2004. Clin. Infect. Dis. 40:1693-1696. http://dx.doi.org/10.1086/430424.
4. Block SL. 2004. Role of influenza vaccine for healthy children in the US. Paediatr. Drugs 6:199-209. http://dx.doi.org/10.2165/00148581-200406040-00001.
5. Loeb M. 2004. Pneumonia in the elderly. Curr. Opin. Infect. Dis. 17:127-130. http://dx.doi.org/10.1097/00001432-200404000-00010.
6. Olshaker JS. 2003. Influenza. Emerg. Med. Clin. North Am. 21:353-361. http://dx.doi.org/10.1016/S0733-8627(03)00018-X.
7. Fiore AE, Bridges CB, Cox NJ. 2009. Seasonal influenza vaccines. Curr. Top. Microbiol. Immunol. 333:43-82. http://dx.doi.org/10.1007/978-3-540-92165-3_3.
8. McElhaney JE. 2005. The unmet need in the elderly: designing new influenza vaccines for older adults. Vaccine 23(Suppl 1):S10-S25. http://dx.doi.org/10.1016/j.vaccine.2005.04.019.
9. Thompson WW, Shay DK, Weintraub E, Brammer L, Bridges CB, Cox NJ, Fukuda K. 2004. Influenza-associated hospitalizations in the United States. JAMA 292:1333-1340. http://dx.doi.org/10.1001/jama.292.11.1333.
10. Rosenberg MR, Casarotto MG. 2010. Coexistence of two adamantane binding sites in the influenza A M2 ion channel. Proc. Natl. Acad. Sci. U. S. A. 107:13866-13871. http://dx.doi.org/10.1073/pnas.1002051107.
11. Bright RA, Medina MJ, Xu X, Perez-Oronoz G, Wallis TR, Davis XM, Povinelli L, Cox NJ, Klimov AI. 2005. Incidence of adamantane resistance among influenza A (H3N2) viruses isolated worldwide from 1994 to 2005: a cause for concern. Lancet 366:1175-1181. http://dx.doi.org/10.1016/S0140-6736(05)67338-2.
12. Fiore AE, Fry A, Shay D, Gubareva L, Bresee JS, Uyeki TM. 2011. Antiviral agents for the treatment and chemoprophylaxis of influenza-recommendations of the Advisory Committee on Immunization Practices (ACIP). MMWR Recomm. Rep. 60:1-24. http://www.cdc.gov/mmwr/preview/mmwrhtml/rr6001a1.htm.
13. Moscona A. 2005. Neuraminidase inhibitors for influenza. N. Engl. J. Med. 353:1363-1373. http://dx.doi.org/10.1056/NEJMra050740.
14. Wright PF, Neumann G, Kawaoka Y. 2007. Orthomyxoviruses, p 1691-1740. In Fields BN, Knipe DM, Howley PM (ed), Fields virology, 5th ed, vol 2. Lippincott Williams & Wilkins, Philadelphia, PA.
15. Palese P, Shaw ML. 2007. Orthomyxoviridae: the viruses and their replication., p 1647-1689. In Fields BN, Knipe DM, Howley PM (ed), Fields virology, 5th ed, vol 2. Lippincott Williams & Wilkins, Philadelphia, PA.
16. Brass AL, Huang IC, Benita Y, John SP, Krishnan MN, Feeley EM, Ryan BJ, Weyer JL, van der Weyden L, Fikrig E, Adams DJ, Xavier RJ, Farzan M, Elledge SJ. 2009. The IFITM proteins mediate cellular resistance to influenzaAH1N1 virus, West Nile virus, and dengue virus. Cell 139:1243-1254. http://dx.doi.org/10.1016/j.cell.2009.12.017.
17. Hao L, Sakurai A, Watanabe T, Sorensen E, Nidom CA, Newton MA, Ahlquist P, Kawaoka Y. 2008. Drosophila RNAi screen identifies host genes important for influenza virus replication. Nature 454:890-893. http://dx.doi.org/10.1038/nature07151.
18. Karlas A, Machuy N, Shin Y, Pleissner K-P, Artarini A, Heuer D, Becker D, Khalil H, Ogilvie LA, Hess S, Maurer AP, Muller E, Wolff T, Rudel T, Meyer TF. 2010. Genome-wide RNAi screen identifies human host factors crucial for influenza virus replication. Nature 463:818-822. http://dx.doi.org/10.1038/nature08760.
19. König R, Stertz S, Zhou Y, Inoue A, Hoffmann HH, Bhattacharyya S, Alamares JG, Tscherne DM, Ortigoza MB, Liang Y, Gao Q, Andrews SE, Bandyopadhyay S, De Jesus P, Tu BP, Pache L, Shih C, Orth A, Bonamy G, Miraglia L, Ideker T, Garcia-Sastre A, Young JA, Palese P, Shaw ML, Chanda SK. 2010. Human host factors required for influenza virus replication. Nature 463:813-817. http://dx.doi.org/10.1038/nature08699.
20. Meliopoulos VA, Andersen LE, Brooks P, Yan X, Bakre A, Coleman JK, Tompkins SM, Tripp RA. 2012. MicroRNA regulation of human protease genes essential for influenza virus replication. PLoS One 7(5): e37169. http://dx.doi.org/10.1371/journal.pone.0037169.
21. Shapira SD, Gat-Viks I, Shum BOV, Dricot A, de Grace MM, Wu L, Gupta PB, Hao T, Silver SJ, Root DE, Hill DE, Regev A, Hacohen N. 2009. A physical and regulatory map of host-influenza interactions reveals pathways in H1N1 infection. Cell 139:1255-1267. http://dx.doi.org/10.1016/j.cell.2009.12.018.
22. Sui B, Bamba D, Weng K, Ung H, Chang S, Van Dyke J, Goldblatt M, Duan R, Kinch MS, Li W-B. 2009. The use of random homozygous gene perturbation to identify novel host-oriented targets for influenza. Virology 387:473-481. http://dx.doi.org/10.1016/j.virol.2009.02.046.
23. Meliopoulos VA, Andersen LE, Birrer KF, Simpson KJ, Lowenthal JW, Bean AG, Stambas J, Stewart CR, Tompkins SM, van Beusechem VW, Fraser I, Mhlanga M, Barichievy S, Smith Q, Leake D, Karpilow J, Buck A, Jona G, Tripp RA. 2012. Host gene targets for novel influenza therapies elucidated by high-throughput RNA interference screens. FASEB J. 26: 1372-1386. http://dx.doi.org/10.1096/fj.11-193466.
24. Perwitasari O, Yan X, Johnson S, White C, Brooks P, Tompkins SM, Tripp RA. 2013. Targeting organic anion transporter 3 with probenecid as a novel anti-influenza A virus strategy. Antimicrob. Agents Chemother. 57:475-483. http://dx.doi.org/10.1128/AAC.01532-12.
25. Whittaker GR. 2001. Intracellular trafficking of influenza virus: clinical implications for molecular medicine. Expert Rev. Mol. Med. 3:1-13. http://dx.doi.org/10.1017/S1462399401002575.
26. Cros JF, Garcia-Sastre A, Palese P. 2005. An unconventional NLS is critical for the nuclear import of the influenza A virus nucleoprotein and ribonucleoprotein. Traffic 6:205-213. http://dx.doi.org/10.1111/j.1600-0854.2005.00263.x.
27. Melen K, Fagerlund R, Franke J, Kohler M, Kinnunen L, Julkunen I. 2003. Importin alpha nuclear localization signal binding sites for STAT1, STAT2, and influenza A virus nucleoprotein. J. Biol. Chem. 278:28193-28200. http://dx.doi.org/10.1074/jbc.M303571200.
28. Weber F, Kochs G, Gruber S, Haller O. 1998. A classical bipartite nuclear localization signal on Thogoto and influenza A virus nucleoproteins. Virology 250:9-18. http://dx.doi.org/10.1006/viro.1998.9329.
29. Boulo S, Akarsu H, Ruigrok RW, Baudin F. 2007. Nuclear traffic of influenza virus proteins and ribonucleoprotein complexes. Virus Res. 124: 12-21. http://dx.doi.org/10.1016/j.virusres.2006.09.013.
30. Elton D, Simpson-Holley M, Archer K, Medcalf L, Hallam R, McCauley J, Digard P. 2001. Interaction of the influenza virus nucleoprotein with the cellular CRM1-mediated nuclear export pathway. J. Virol. 75:408-419. http://dx.doi.org/10.1128/JVI.75.1.408-419.2001.
31. Nayak DP, Hui EK, Barman S. 2004. Assembly and budding of influenza virus. Virus Res. 106:147-165. http://dx.doi.org/10.1016/j.virusres.2004.08.012.
32. Paterson D, Fodor E. 2012. Emerging roles for the influenza A virus nuclear export protein (NEP). PLoS Pathog. 8(12):e1003019. http://dx.doi.org/10.1371/journal.ppat.1003019.
33. Paragas J, Talon J, O'Neill RE, Anderson DK, Garcia-Sastre A, Palese P. 2001. Influenza B and C virus NEP (NS2) proteins possess nuclear export activities. J. Virol. 75:7375-7383. http://dx.doi.org/10.1128/JVI.75.16.7375-7383.2001.
34. Ossareh-Nazari B, Gwizdek C, Dargemont C. 2001. Protein export from the nucleus. Traffic 2:684-689. http://dx.doi.org/10.1034/j.1600-0854.2001.21002.x.
35. Etchin J, Sun Q, Kentsis A, Farmer A, Zhang ZC, Sanda T, Mansour MR, Barcelo C, McCauley D, Kauffman M, Shacham S, Christie AL, Kung AL, Rodig SJ, Chook YM, Look AT. 2013. Antileukemic activity of nuclear export inhibitors that spare normal hematopoietic cells. Leukemia 27:66-74. http://dx.doi.org/10.1038/leu.2012.219.
36. Kudo N, Matsumori N, Taoka H, Fujiwara D, Schreiner EP, Wolff B, Yoshida M, Horinouchi S. 1999. Leptomycin B inactivates CRM1/exportin 1 by covalent modification at a cysteine residue in the central conserved region. Proc. Natl. Acad. Sci. U. S. A. 96:9112-9117. http://dx.doi.org/10.1073/pnas.96.16.9112.
37. Weis K. 2002. Nucleocytoplasmic transport: cargo trafficking across the border. Curr. Opin. Cell Biol. 14:328-335. http://dx.doi.org/10.1016/S0955-0674(02)00337-X.
38. Sun Q, Carrasco YP, Hu Y, Guo X, Mirzaei H, Macmillan J, Chook YM. 2013. Nuclear export inhibition through covalent conjugation and hydrolysis of leptomycin B by CRM1. Proc. Natl. Acad. Sci. U. S. A. 110:1303-1308. http://dx.doi.org/10.1073/pnas.1217203110.
39. Mutka SC, Yang WQ, Dong SD, Ward SL, Craig DA, Timmermans PB, Murli S. 2009. Identification of nuclear export inhibitors with potent anticancer activity in vivo. Cancer Res. 69:510-517. http://dx.doi.org/10.1158/0008-5472.CAN-08-0858.
40. Newlands ES, Rustin GJ, Brampton MH. 1996. Phase I trial of elactocin. Br. J. Cancer 74:648-649. http://dx.doi.org/10.1038/bjc.1996.415.
41. Etchin J, Sanda T, Mansour MR, Kentsis A, Montero J, Le BT, Christie AL, McCauley D, Rodig SJ, Kauffman M, Shacham S, Stone R, Letai A, Kung AL, Thomas Look A. 2013. KPT-330 inhibitor of CRM1 (XPO1)-mediated nuclear export has selective anti-leukaemic activity in preclinical models of T-cell acute lymphoblastic leukaemia and acute myeloid leukaemia. Br. J. Haematol. 161:117-127. http://dx.doi.org/10.1111/bjh.12231.
42. Lapalombella R, Sun Q, Williams K, Tangeman L, Jha S, Zhong Y, Goettl V, Mahoney E, Berglund C, Gupta S, Farmer A, Mani R, Johnson AJ, Lucas D, Mo X, Daelemans D, Sandanayaka V, Shechter S, Mc-Cauley D, Shacham S, Kauffman M, Chook YM, Byrd JC. 2012. Selective inhibitors of nuclear export show that CRM1/XPO1 is a target in chronic lymphocytic leukemia. Blood 120:4621-4634. http://dx.doi.org/10.1182/blood-2012-05-429506.
43. Azmi AS, Aboukameel A, Bao B, Sarkar FH, Philip PA, Kauffman M, Shacham S, Mohammad RM. 2013. Selective inhibitors of nuclear export block pancreatic cancer cell proliferation and reduce tumor growth in mice. Gastroenterology 144:447-456. http://dx.doi.org/10.1053/j.gastro.2012.10.036.
44. Ranganathan P, Yu X, Na C, Santhanam R, Shacham S, Kauffman M, Walker A, Klisovic R, Blum W, Caligiuri M, Croce CM, Marcucci G, Garzon R. 2012. Preclinical activity of a novel CRM1 inhibitor in acute myeloid leukemia. Blood 120:1765-1773. http://dx.doi.org/10.1182/blood-2012-04-423160.
45. Tai YT, Landesman Y, Acharya C, Calle Y, Zhong MY, Cea M, Tannenbaum D, Cagnetta A, Reagan M, Munshi AA, Senapedis W, Saint-Martin JR, Kashyap T, Shacham S, Kauffman M, Gu Y, Wu L, Ghobrial I, Zhan F, Kung AL, Schey SA, Richardson P, Munshi NC, Anderson KC. 2014. CRM1 inhibition induces tumor cell cytotoxicity and impairs osteoclastogenesis in multiple myeloma: molecular mechanisms and therapeutic implications. Leukemia 28:155-165. http://dx.doi.org/10.1038/leu.2013.115.
46. Zhang K, Wang M, Tamayo AT, Shacham S, Kauffman M, Lee J, Zhang L, Ou Z, Li C, Sun L, Ford RJ, Pham LV. 2013. Novel selective inhibitors of nuclear export CRM1 antagonists for therapy in mantle cell lymphoma. Exp. Hematol. 41:67-78e64. http://dx.doi.org/10.1016/j.exphem.2012.09.002.
47. Xu D, Grishin NV, Chook YM. 2012. NESdb: a database of NEScontainingCRM1cargoes. Mol. Biol. Cell 23:3673-3676. http://dx.doi.org/10.1091/mbc.E12-01-0045.
48. London CA, Bernabe LF, Barnard S, Kisseberth WC, Borgatti A, Henson M, Wilson H, Jensen K, Ito D, Modiano JF, Bear MD, Pennell ML, Saint-Martin J-R, McCauley D, Kauffman M, Shacham S. 2014. Preclinical evaluation of the novel, orally bioavailable selective inhibitor of nuclear export (SINE) KPT-335 in spontaneous canine cancer: results of a phase I study. PLoS One 9(2):e87585. http://dx.doi.org/10.1371/journal.pone.0087585.
49. Cejka D, Losert D, Wacheck V. 2006. Short interfering RNA (siRNA): tool or therapeutic? Clin. Sci. 110:47-58. http://dx.doi.org/10.1042/CS20050162.
50. Kuruvilla J, Gutierrez M, Shah B, Gabrail N, Brown P, Stone R, Garzon R, Savona M, Baz R, Mau-Sorensen M, Davids M, Byrd J, Shacham S, Rashal T, Yau CY, McCauley D, Saint-Martin J-R, McCartney J, Landesman Y, Klebanov B, Pond G, Oza A, Kauffman M, Mirza MR. 2013. Preliminary evidence of anti-tumor activity of selinexor (KPT-330) in a phase I trial of a first-in-class oral selective inhibitor of nuclear export (SINE) in patients (pts) with relapsed/refractory non-Hodgkin's lymphoma (NHL) and chronic lymphocytic leukemia (CLL), abstr. 90. In Abstr. 55th Annu. Meet. Am. Soc. Hematol., New Orleans, LA.
51. Mau-Sorensen M, Razak AR, Mahipal A, Mahaseth H, Gerecitano JF, Shacham S, Yau CY, Lassen U, Shields AF, McCauley D, Cooksey J, Tan DSP, Rashal T, Shacham E, Landesman Y, Pond G, Oza AM, Kauffman M, Siu LL, Mirza MR. 2013. Safety and anti-tumor activity of KPT-330, a first-in-class oral XPO1 selective inhibitor of nuclear export-phase I study expanded with colon cancer cohort. Gastrointestinal Cancers Symposium. American Society of Clinical Oncology, San Francisco, CA.
52. Savona M, Garzon R, Brown P, Yee K, Lancet J, Gutierrez M, Gabrail N, Mau-Sorensen M, Baz R, Shacham S, Rashal T, Yau CY, McCauley D, Saint-Martin J-R, McCartney J, Landesman Y, Klebanov B, Pond G, Oza A, Kauffman M, Mirza MR, Stone RM. 2013. Phase I trial of selinexor (KPT-330), a first-in-class oral selective inhibitor of nuclear export (SINE) in patients (pts) with advanced acute myelogenous leukemia (AML), poster 1. In Abstr. 55th Annu. Meet. Am. Soc. Hematol., New Orleans, LA.
53. Woolcock PR. 2008. Avian influenza virus isolation and propagation in chicken eggs. Methods Mol. Biol. 436:35-46. http://dx.doi.org/10.1007/978-1-59745-279-3_6.
54. Reed LJ, Muench H. 1938. A simple method of estimating fifty percent endpoints. Am. J. Hyg. 27:493-497.
55. Szretter KJ, Balish AL, Katz JM. 2006. Influenza: propagation, quantification, and storage. Curr. Protoc. Microbiol. 15:Unit 15G.1. http://dx.doi.org/10.1002/0471729256.mc15g01s3.
56. Wang W, Budhu A, Forgues M, Wang XW. 2005. Temporal and spatial control of nucleophosmin by the Ran-Crm1 complex in centrosome duplication. Nat. Cell Biol. 7:823-830. http://dx.doi.org/10.1038/ncb1282.
57. Jones RE, Zheng W, McKew JC, Chen CZ. 2013. An alternative direct compound dispensing method using the HP D300 digital dispenser. J. Lab. Autom. 18:367-374. http://dx.doi.org/10.1177/2211068213491094.
58. Wang X, Spandidos A, Wang H, Seed B. 2012. PrimerBank: a PCR primer database for quantitative gene expression analysis, 2012 update. Nucleic Acids Res. 40:D1144-D1149. http://dx.doi.org/10.1093/nar/gkr1013.
59. Kawakami E, Watanabe T, Fujii K, Goto H, Watanabe S, Noda T, Kawaoka Y. 2011. Strand-specific real-time RT-PCR for distinguishing influenza vRNA, cRNA, and mRNA. J. Virol. Methods 173:1-6. http://dx.doi.org/10.1016/j.jviromet.2010.12.014.
60. Driskell EA, Jones CA, Stallknecht DE, Howerth EW, Tompkins SM. 2010. Avian influenza virus isolates from wild birds replicate and cause disease in a mouse model of infection. Virology 399:280-289. http://dx.doi.org/10.1016/j.virol.2010.01.005.
61. Le VL, Courtney CL, Steel J, Compans RW. 2013. Closely related influenza viruses induce contrasting respiratory tract immunopathology. PLoS One 8(9):e76708. http://dx.doi.org/10.1371/journal.pone.0076708.
62. Pleschka S, Wolff T, Ehrhardt C, Hobom G, Planz O, Rapp UR, Ludwig S. 2001. Influenza virus propagation is impaired by inhibition of the Raf/MEK/ERK signalling cascade. Nat. Cell Biol. 3:301-305. http://dx.doi.org/10.1038/35060098.
63. Watanabe K, Takizawa N, Katoh M, Hoshida K, Kobayashi N, Nagata K. 2001. Inhibition of nuclear export of ribonucleoprotein complexes of influenza virus by leptomycin B. Virus Res. 77:31-42. http://dx.doi.org/10.1016/S0168-1702(01)00263-5.
64. Bernasconi D, Amici C, La Frazia S, Ianaro A, Santoro MG. 2005. The IκB kinase is a key factor in triggering influenza A virus-induced inflammatory cytokine production in airway epithelial cells. J. Biol. Chem. 280: 24127-24134. http://dx.doi.org/10.1074/jbc.M413726200.
65. Josset L, Belser JA, Pantin-Jackwood MJ, Chang JH, Chang ST, Belisle SE, Tumpey TM, Katze MG. 2012. Implication of inflammatory macrophages, nuclear receptors, and interferon regulatory factors in increased virulence of pandemic 2009 H1N1 influenza A virus after host adaptation. J. Virol. 86:7192-7206. http://dx.doi.org/10.1128/JVI.00563-12.
66. Hamuza M, Landesman Y, Klebanov B, Kauffman M, Shacham S, Endres J, Fox DA, McCauley D. 2013. Novel selective inhibitors of nuclear export attenuate inflammation and prevent bone mineral density loss in multiple preclinical models of rheumatoid arthritis. Arthritis Rheum. 65(Suppl 10): 1727. (Abstract.).
67. Tripp RA. 2004. Pathogenesis of respiratory syncytial virus infection. Viral Immunol. 17:165-181. http://dx.doi.org/10.1089/0882824041310513.
68. Ghildyal R, Ho A, Dias M, Soegiyono L, Bardin PG, Tran KC, Teng MN, Jans DA. 2009. The respiratory syncytial virus matrix protein possesses a Crm1-mediated nuclear export mechanism. J. Virol. 83:5353-5362. http://dx.doi.org/10.1128/JVI.02374-08.
69. Ghildyal R, Ho A, Wagstaff KM, Dias MM, Barton CL, Jans P, Bardin P, Jans DA. 2005. Nuclear import of the respiratory syncytial virus matrix protein is mediated by importin beta1 independent of importin alpha. Biochemistry 44:12887-12895. http://dx.doi.org/10.1021/bi050701e.
70. Rawlinson SM, Pryor MJ, Wright PJ, Jans DA. 2009. CRM1-mediated nuclear export of dengue virus RNA polymerase NS5 modulates interleukin-8 induction and virus production. J. Biol. Chem. 284:15589-15597. http://dx.doi.org/10.1074/jbc.M808271200.
71. Daelemans D, Afonina E, Nilsson J, Werner G, Kjems J, De Clercq E, Pavlakis GN, Vandamme A-M. 2002. A synthetic HIV-1 Rev. inhibitor interfering with the CRM1-mediated nuclear export. Proc. Natl. Acad. Sci. U. S. A. 99:14440-14445. http://dx.doi.org/10.1073/pnas.212285299.
72. Pollard VW, Malim MH. 1998. The HIV-1 Rev protein. Annu. Rev. Microbiol. 52:491-532. http://dx.doi.org/10.1146/annurev.micro.52.1.491.
73. Sanchez V, Mahr JA, Orazio NI, Spector DH. 2007. Nuclear export of the human cytomegalovirus tegument protein pp65 requires cyclindependent kinase activity and the Crm1 exporter. J. Virol. 81:11730-11736. http://dx.doi.org/10.1128/JVI.02760-06.
74. Williams P, Verhagen J, Elliott G. 2008. Characterization of a CRM1-dependent nuclear export signal in the C terminus of herpes simplex virus type 1 tegument protein UL47. J. Virol. 82:10946-10952. http://dx.doi.org/10.1128/JVI.01403-08.
75. Freundt EC, Yu L, Park E, Lenardo MJ, Xu X-N. 2009. Molecular determinants for subcellular localization of the severe acute respiratory syndrome coronavirus open reading frame 3b protein. J. Virol. 83:6631-6640. http://dx.doi.org/10.1128/JVI.00367-09.
76. Dong X, Biswas A, Suel KE, Jackson LK, Martinez R, Gu H, Chook YM. 2009. Structural basis for leucine-rich nuclear export signal recognition by CRM1. Nature 458:1136-1141. http://dx.doi.org/10.1038/nature07975.
77. Turner JG, Dawson J, Sullivan DM. 2012. Nuclear export of proteins and drug resistance in cancer. Biochem. Pharmacol. 83:1021-1032. http://dx.doi.org/10.1016/j.bcp.2011.12.016.
78. Boons E, Vanstreels E, Vercruysse T, Shacham S, Landesman Y, Baluglu E, Tamir S, Pannecouque C, Daelemans D. 2013. Replication inhibition by small-molecule inhibitors targeting the HIV Rev-CRM1/XPO1 interaction, abstr 20. Abstr. 26th Int. Conf. Antiviral Res., San Francisco, CA.
79. Huang TT, Kudo N, Yoshida M, Miyamoto S. 2000. A nuclear export signal in the N-terminal regulatory domain of Iκ Bα controls cytoplasmic localization of inactive NF-κ B/Iκ Bα complexes. Proc. Natl. Acad. Sci. U. S. A. 97:1014-1019. http://dx.doi.org/10.1073/pnas.97.3.1014.
80. Tam WF, Lee LH, Davis L, Sen R. 2000. Cytoplasmic sequestration of Rel proteins by IκBα requires CRM1-dependent nuclear export. Mol. Cell. Biol. 20:2269-2284. http://dx.doi.org/10.1128/MCB.20.6.2269-2284.2000.
81. Arenzana-Seisdedos F, Thompson J, Rodriguez MS, Bachelerie F, Thomas D, Hay RT. 1995. Inducible nuclear expression of newly synthesized I kappa B alpha negatively regulates DNA-binding and transcriptional activities of NF-kappa B. Mol. Cell. Biol. 15:2689-2696.
82. Arenzana-Seisdedos F, Turpin P, Rodriguez M, Thomas D, Hay RT, Virelizier JL, Dargemont C. 1997. Nuclear localization of I kappa B alpha promotes active transport of NF-kappa B from the nucleus to the cytoplasm. J. Cell Sci. 110:369-378.
83. Lee S-H, Hannink M. 2002. Characterization of the nuclear import and export functions of IκBe. J. Biol. Chem. 277:23358-23366. http://dx.doi.org/10.1074/jbc.M111559200.
84. Brown KD, Claudio E, Siebenlist U. 2008. The roles of the classical and alternative nuclear factor-kappaB pathways: potential implications for autoimmunity and rheumatoid arthritis. Arthritis Res. Ther. 10:212. http://dx.doi.org/10.1186/ar2457.
85. O'Connor S, Shumway S, Miyamoto S. 2005. Inhibition of IkappaBalpha nuclear export as an approach to abrogate nuclear factor-kappaBdependent cancer cell survival. Mol. Cancer Res. 3:42-49. http://mcr.aacrjournals.org/content/3/1/42.long.
86. Zerfaoui M, Errami Y, Naura AS, Suzuki Y, Kim H, Ju J, Liu T, Hans CP, Kim JG, Abd Elmageed ZY, Koochekpour S, Catling A, Boulares AH. 2010. Poly(ADP-ribose) polymerase-1 is a determining factor in Crm1-mediated nuclear export and retention of p65 NF-kappa B upon TLR4 stimulation. J. Immunol. 185:1894-1902. http://dx.doi.org/10.4049/jimmunol.1000646.
87. Zhang Y, Sun H, Fan L, Ma Y, Sun Y, Pu J, Yang J, Qiao J, Ma G, Liu J. 2012. Acute respiratory distress syndrome induced by a swine 2009 H1N1 variant in mice. PLoS One 7(1):e29347. http://dx.doi.org/10.1371/journal.pone.0029347.